MA39020A1 - Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique - Google Patents

Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique

Info

Publication number
MA39020A1
MA39020A1 MA39020A MA39020A MA39020A1 MA 39020 A1 MA39020 A1 MA 39020A1 MA 39020 A MA39020 A MA 39020A MA 39020 A MA39020 A MA 39020A MA 39020 A1 MA39020 A1 MA 39020A1
Authority
MA
Morocco
Prior art keywords
dihydro
salts
tetrahydropyrimidine
benzoxazol
inden
Prior art date
Application number
MA39020A
Other languages
English (en)
French (fr)
Inventor
Chantal Fürstner
Jens Ackerstaff
Birgit Keil
Britta Olenik
Martin-Holger Hinz
Mario Jeske
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA39020A1 publication Critical patent/MA39020A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA39020A 2013-11-08 2014-11-05 Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique MA39020A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192177 2013-11-08
PCT/EP2014/073801 WO2015067652A1 (de) 2013-11-08 2014-11-05 Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure

Publications (1)

Publication Number Publication Date
MA39020A1 true MA39020A1 (fr) 2017-04-28

Family

ID=49552231

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39020A MA39020A1 (fr) 2013-11-08 2014-11-05 Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique

Country Status (33)

Country Link
US (1) US9926305B2 (pt)
EP (1) EP3066097B1 (pt)
JP (1) JP6446051B2 (pt)
KR (1) KR102351418B1 (pt)
CN (1) CN105658647B (pt)
AP (1) AP2016009181A0 (pt)
AU (1) AU2014345599B2 (pt)
BR (1) BR112016010253A8 (pt)
CA (1) CA2929780C (pt)
CL (1) CL2016001096A1 (pt)
CY (1) CY1119520T1 (pt)
DK (1) DK3066097T3 (pt)
EA (1) EA033132B1 (pt)
ES (1) ES2645480T3 (pt)
HK (1) HK1222171A1 (pt)
HR (1) HRP20171603T1 (pt)
HU (1) HUE035021T2 (pt)
IL (1) IL245407B (pt)
LT (1) LT3066097T (pt)
MA (1) MA39020A1 (pt)
ME (1) ME02907B (pt)
MX (1) MX366848B (pt)
MY (1) MY190108A (pt)
NO (1) NO3066097T3 (pt)
PH (1) PH12016500853A1 (pt)
PL (1) PL3066097T3 (pt)
PT (1) PT3066097T (pt)
RS (1) RS56509B1 (pt)
SA (1) SA516371082B1 (pt)
SI (1) SI3066097T1 (pt)
TN (1) TN2016000170A1 (pt)
UA (1) UA117686C2 (pt)
WO (1) WO2015067652A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
WO2018197333A1 (en) * 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
TW202404601A (zh) * 2022-04-05 2024-02-01 加拿大商索科普拉健康與人類科學兩合公司 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4175887B2 (ja) * 2000-10-19 2008-11-05 日本化薬株式会社 新規血管狭窄治療剤または予防剤
AT511788A1 (de) 2011-07-29 2013-02-15 Georg Dr Gaul Vorrichtung zur vorgebbaren anordnung eines stents
AU2013230671B2 (en) * 2012-03-05 2016-12-15 Gratuk Technologies Pty Ltd Dietary supplement
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
US9695131B2 (en) * 2013-11-08 2017-07-04 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors

Also Published As

Publication number Publication date
NO3066097T3 (pt) 2018-01-13
JP2016535096A (ja) 2016-11-10
BR112016010253A8 (pt) 2021-06-22
DK3066097T3 (da) 2017-11-06
KR102351418B1 (ko) 2022-01-17
CN105658647A (zh) 2016-06-08
PT3066097T (pt) 2017-11-10
HK1222171A1 (zh) 2017-06-23
PL3066097T3 (pl) 2018-01-31
MY190108A (en) 2022-03-29
AU2014345599B2 (en) 2019-02-14
US20160289220A1 (en) 2016-10-06
EP3066097A1 (de) 2016-09-14
MX366848B (es) 2019-07-26
PH12016500853B1 (en) 2016-06-20
CY1119520T1 (el) 2018-03-07
CA2929780C (en) 2022-03-22
KR20160078980A (ko) 2016-07-05
UA117686C2 (uk) 2018-09-10
SI3066097T1 (sl) 2017-12-29
AU2014345599A1 (en) 2016-05-19
CA2929780A1 (en) 2015-05-14
CL2016001096A1 (es) 2016-12-23
HUE035021T2 (en) 2018-03-28
IL245407B (en) 2019-10-31
WO2015067652A1 (de) 2015-05-14
ME02907B (me) 2018-04-20
NZ719532A (en) 2021-06-25
EA033132B1 (ru) 2019-08-30
CN105658647B (zh) 2019-09-06
EA201600381A1 (ru) 2016-10-31
AP2016009181A0 (en) 2016-04-30
BR112016010253A2 (pt) 2017-08-08
ES2645480T3 (es) 2017-12-05
LT3066097T (lt) 2018-02-12
EP3066097B1 (de) 2017-08-16
PH12016500853A1 (en) 2016-06-20
SA516371082B1 (ar) 2019-05-16
JP6446051B2 (ja) 2018-12-26
US9926305B2 (en) 2018-03-27
IL245407A0 (en) 2016-06-30
RS56509B1 (sr) 2018-02-28
HRP20171603T1 (hr) 2017-12-01
TN2016000170A1 (en) 2017-10-06
MX2016005971A (es) 2016-08-11

Similar Documents

Publication Publication Date Title
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
TR201904614T4 (tr) Novel pyrazole derivative.
MA40219B1 (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
MA44820B1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
JO3781B1 (ar) مشتقات الكينولون
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA39020A1 (fr) Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA35268B1 (fr) 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA38857B1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA38009B1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
TH1601002185A (th) เกลือแบบใหม่ของ 1-(3-เมธิล-2-ออกโซ-2,3-ไดไฮโดร-1,3-เบนซอกซาโซล-6-อิล)-2,4- ไดออกโซ-3-[(1r)-4-(ไตรฟลูออโรเมธิล)-2,3-ไดไฮโดร-1h-อินดิน-1-อิล]-1,2,3,4- เตตระไฮโดรไพริมิดีน-5-คาร์บอกซิลิกแอซิดและการใช้เกลือดังกล่าว
MA33329B1 (fr) 17ß-ALKYL-17A-OXY-ESTRATRIÈNES